Therefore, it is expected that PCa patients bearing high grade and stage tumor may benefit from the IL-27 immunostimulatory [3] and anti-angiogenic [5] effects on the tumor microenvironment, whereas, the full anti-cancer potential of IL-27 may be exploited in patients who are diagnosed with well-differentiated, slow growing and localized PCa. The gene discussed is IL27; the disease is posterior cortical atrophy.